Tetracycline for Multiple Sclerosis?

    loading  Checking for direct PDF access through Ovid

Abstract

One hundred forty-two patients within 180 days of their first demyelinating event were randomized to minocycline 100 mg BID vs. placebo. The unadjusted risk of conversion to multiple sclerosis within six months after randomization was 61.0% in the placebo group and 33.4% in the minocycline group. At 24 months, the effect of minocycline was not statistically significant.

Related Topics

    loading  Loading Related Articles